AVADEL PHARMACEUTICALS PLC: depreciation expense
Depreciation expense for AVADEL PHARMACEUTICALS PLC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All AVADEL PHARMACEUTICALS PLC financial histories
What this measure means
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
Exact concept: us-gaap:Depreciation. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2010-01-01 to 2024-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2024-01-01 | 2024-12-31 | 132,000 | USD | 2025-03-03 | 10-K · 0001012477-25-000010 |
| 2023-01-01 | 2023-12-31 | 254,000 | USD | 2025-03-03 | 10-K · 0001012477-25-000010 |
| 2022-01-01 | 2022-12-31 | 162,000 | USD | 2025-03-03 | 10-K · 0001012477-25-000010 |
| 2021-01-01 | 2021-12-31 | 97,000 | USD | 2024-02-29 | 10-K · 0001012477-24-000008 |
| 2020-01-01 | 2020-12-31 | 287,000 | USD | 2022-03-16 | 10-K · 0001012477-22-000004 |
| 2019-01-01 | 2019-12-31 | 459,000 | USD | 2022-03-16 | 10-K · 0001012477-22-000004 |
| 2018-01-01 | 2018-12-31 | 811,000 | USD | 2021-03-09 | 10-K · 0001012477-21-000004 |
| 2017-01-01 | 2017-12-31 | 1,224,000 | USD | 2020-03-16 | 10-K · 0001012477-20-000007 |
| 2016-01-01 | 2016-12-31 | 601,000 | USD | 2019-03-15 | 10-K · 0001012477-19-000002 |
| 2015-01-01 | 2015-12-31 | 568,000 | USD | 2018-03-16 | 10-K · 0001012477-18-000008 |
| 2014-01-01 | 2014-12-31 | 681,000 | USD | 2017-03-28 | 10-K · 0001012477-17-000021 |
| 2013-01-01 | 2013-12-31 | 774,000 | USD | 2016-03-15 | 10-K · 0001144204-16-088149 |
| 2012-01-01 | 2012-12-31 | 44,000 | USD | 2014-04-30 | 20-F/A · 0001144204-14-026504 |
| 2011-01-01 | 2011-12-31 | 56,000 | USD | 2014-04-30 | 20-F/A · 0001144204-14-026504 |
| 2010-01-01 | 2010-12-31 | 47,000 | USD | 2013-04-30 | 20-F · 0001144204-13-025123 |
Related financial histories
- AVADEL PHARMACEUTICALS PLC: total assets
- AVADEL PHARMACEUTICALS PLC: total liabilities
- AVADEL PHARMACEUTICALS PLC: stockholders equity
- AVADEL PHARMACEUTICALS PLC: cash and cash equivalents
- AVADEL PHARMACEUTICALS PLC: net income or loss
- AVADEL PHARMACEUTICALS PLC: operating cash flow
- AVADEL PHARMACEUTICALS PLC: capital expenditure payments
- AVADEL PHARMACEUTICALS PLC: contract revenue excluding tax
- AVADEL PHARMACEUTICALS PLC: financing cash flow
- AVADEL PHARMACEUTICALS PLC: investing cash flow
- AVADEL PHARMACEUTICALS PLC: retained earnings or deficit
- AVADEL PHARMACEUTICALS PLC: basic weighted-average shares
- AVADEL PHARMACEUTICALS PLC: diluted weighted-average shares
- AVADEL PHARMACEUTICALS PLC: basic earnings per share
- AVADEL PHARMACEUTICALS PLC: diluted earnings per share
- AVADEL PHARMACEUTICALS PLC: income tax expense or benefit
- AVADEL PHARMACEUTICALS PLC: net property, plant and equipment
- AVADEL PHARMACEUTICALS PLC: share-based compensation expense
- AVADEL PHARMACEUTICALS PLC: operating income or loss
- AVADEL PHARMACEUTICALS PLC: current assets
- AVADEL PHARMACEUTICALS PLC: interest expense
- AVADEL PHARMACEUTICALS PLC: current liabilities
- AVADEL PHARMACEUTICALS PLC: current accounts payable
- AVADEL PHARMACEUTICALS PLC: goodwill carrying amount
- AVADEL PHARMACEUTICALS PLC: net finite-lived intangible assets
- AVADEL PHARMACEUTICALS PLC: net current accounts receivable
- AVADEL PHARMACEUTICALS PLC: common-stock repurchase payments
- AVADEL PHARMACEUTICALS PLC: operating expenses
- AVADEL PHARMACEUTICALS PLC: net inventory
- AVADEL PHARMACEUTICALS PLC: gross profit
- AVADEL PHARMACEUTICALS PLC: selling, general and administrative expense
- AVADEL PHARMACEUTICALS PLC: research and development expense
- AVADEL PHARMACEUTICALS PLC: common shares outstanding
- AVADEL PHARMACEUTICALS PLC: cash including restricted cash
- AVADEL PHARMACEUTICALS PLC: accumulated other comprehensive income or loss
- AVADEL PHARMACEUTICALS PLC: operating lease right-of-use asset
- AVADEL PHARMACEUTICALS PLC: operating lease liability
- AVADEL PHARMACEUTICALS PLC: long-term debt
- AVADEL PHARMACEUTICALS PLC: gross property, plant and equipment
- AVADEL PHARMACEUTICALS PLC: accumulated depreciation on property, plant and equipment
- AVADEL PHARMACEUTICALS PLC: net intangible assets excluding goodwill
- AVADEL PHARMACEUTICALS PLC: other noncurrent assets
- AVADEL PHARMACEUTICALS PLC: other noncurrent liabilities
- AVADEL PHARMACEUTICALS PLC: accrued current liabilities
- AVADEL PHARMACEUTICALS PLC: prepaid expenses and other current assets
- AVADEL PHARMACEUTICALS PLC: net deferred tax assets
- AVADEL PHARMACEUTICALS PLC: pre-tax income or loss from continuing operations
- AVADEL PHARMACEUTICALS PLC: comprehensive income or loss
- AVADEL PHARMACEUTICALS PLC: depreciation, depletion and amortization
- AVADEL PHARMACEUTICALS PLC: amortization of intangible assets
- AVADEL PHARMACEUTICALS PLC: other nonoperating income or expense
- AVADEL PHARMACEUTICALS PLC: current income tax expense or benefit
- AVADEL PHARMACEUTICALS PLC: deferred income tax expense or benefit
- AVADEL PHARMACEUTICALS PLC: interest paid, net
- AVADEL PHARMACEUTICALS PLC: income taxes paid, net
- AVADEL PHARMACEUTICALS PLC: operating lease payments
- AVADEL PHARMACEUTICALS PLC: change in accounts receivable
- AVADEL PHARMACEUTICALS PLC: change in inventories
- AVADEL PHARMACEUTICALS PLC: change in accounts payable
Inspect the source
- Entity
- AVADEL PHARMACEUTICALS PLC / CIK 0001012477
- Captured
- 2026-09-21T17:17:59.655Z
- SEC response SHA-256
2657776e70a723d06828aae0240a4344524424707ea355b9c13371a1623553a0
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001012477.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))